NEW DELHI, India, March 12, 2018 -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announces that N. Venkat, chief executive officer and co-founder of Vyome Biosciences, will present at the Cowen and Company 38th Annual Health Care Conference at 11:30 a.m. EDT on Tuesday, March 13, 2018, at the Boston Marriott Copley Plaza, Boston.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic resistant acne being studied in phase 2 trials. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in and @VyomeBio.
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]


Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Anta Sports Expands Global Footprint With Strategic Puma Stake
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Explores AI Content Marketplace With Media Publishers
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Washington Post Publisher Will Lewis Steps Down After Layoffs
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



